|
|
Volumn 94, Issue 21, 2002, Pages 1596-1597
|
|
Despite concerns, FDA panel backs EGFR inhibitor
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
IMATINIB;
PLATINUM DERIVATIVE;
TAXANE DERIVATIVE;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
CANCER SURVIVAL;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG RESPONSE;
FOOD AND DRUG ADMINISTRATION;
HEAD AND NECK CANCER;
HUMAN;
LUNG NON SMALL CELL CANCER;
NOTE;
PRIORITY JOURNAL;
RECEPTOR BINDING;
SIDE EFFECT;
|
|
EID: 0037032501
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.21.1596 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|